SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BSD Medical (Long Term Investment Oriented)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pleonastic who wrote (112)2/13/2013 3:41:48 PM
From: geoffrey Wren  Read Replies (1) of 178
 
Pleo

The point about tumors consisting of differentiated cells is valid, but that sort of reasoning gets into the equation earlier: whether to explore heat-ablation as a type of treatment.

At this point, the needed information is effectiveness in actual trials.

For metastasized cancer, the important information is longevity after treatment for patients in similar classes, as well as some sort of qualify of life comparison, as even if one treatment provides no longevity superiority, it can be better re: side effects. I suppose some of that information is trickling in now.

For initial treatment, the important information is effectiveness at the apparent complete elimination of tumor in initial treatment, 5 year and 10 survival rates.

There is a lot of information yet to be gathered. There is reason to be hopeful, but cancer like HIV and malaria has a long history of being resistant to treatment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News